Childhood brain tumours and growth hormone treatment

Growth Hormone Therapy in Pediatrics-20 Years of KIGS

Volumn , Issue , 2007, Pages 240-249

  Jostel, Andreas ^a   Shalet, Stephen M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864555723     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000101821     Document Type: Chapter

References (51)

1. Pollack IF: Brain tumors in children. N Engl J Med 1994;331:1500-1507.
2. Levy AS: Brain tumors in children: evaluation and management. Curr Probl Pediatr Adolesc Health Care 2005;35:230-245.
3. Kleihues P, Cavenee WK: Pathology and Genetics of Tumours of the Ner-vous System. Lyon, IARC Press, 2000.
4. US Cancer Statistics Working Group: United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta, US Department of Health and Human Ser-vices, Centers for Disease Control and Prevention and National Cancer Insti-tute, 2005. http://www.cdc.gov/cancer/npcr/uscs/pdf/2002_USCS.pdf (ac-cessed June 12, 2006).
5. Mc Nally RJ, Kelsey AM, Cairns DP, Taylor GM, Eden OB, Birch JM: Tempo-ral increases in the incidence of child-hood solid tumors seen in Northwest England (1954-1998) are likely to be real. Cancer 2001;92:1967-1976.
6. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neuro-surg Focus 2006;20:E1.
7. Smith MA, Freidlin B, Ries LA, Simon R: Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 1998;90:1269-1277.
8. Ron E, Modan B, Boice JD Jr, Alfandary E, Stovall M, Chetrit A, Katz L, et al: Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033-1039.
9. Schuz J, Kaletsch U, Kaatsch P, Meinert R, Michaelis J: Risk factors for pediatric tumors of the central nervous system: results from a German population based case control study. Med Pediatr Oncol 2001;36:274-282.
10. Sklar CA: Childhood brain tumors. J Pediatr Endocrinol Metab 2002;15(suppl 2):669-673.
11. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, et al: Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-560.
12. Merchant TE, Jenkins JJ, Burger PC, Sanford RA, Sherwood SH, Jones-Wallace D, Heideman RL, et al: Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 2002;53:52-57.
13. Gilles FH, Brown WD, Leviton A, Tavare CJ, Adelman L, Rorke LB, Davis RL, et al: Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors. Children Brain Tumor Consortium. Cancer 2000;88:1477-1483.
14. Bernhardtsen T, Laursen H, Bojsen Moller M, Gjerris F: Sub classification of lowgrade cerebellar astrocytoma: is it clinically meaningful? Childs Nerv Syst 2003;19:729-735.
15. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-442.
16. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22:994-998.
17. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346:420-427.
18. Ljubimova JY, Fugita M, Khazenzon NM, Das A, Pikul BB, Newman D, Sekiguchi K, et al: Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer 2004;101:604-612.
19. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, et al: Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-993.
20. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, et al:Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005;23:7951-7957.
21. Saito T, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Arifin MT, Arita K, et al: Prognosis of cerebellar glioblasto-mas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res 2006;26:1351-1357. References1 Pollack IF: Brain tumors in children. N
22. Halatsch ME, Schmidt U, Behnke Mursch J, Unterberg A, Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006;32:74-89.
23. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, Mier W, et al: PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver operating-characteristic analysis. J Nucl Med 2004;45:579-586.
24. Gupta N, Banerjee A, Haas Kogan D: Pediatric CNS Tumors. Berlin, Springer, 2004.
25. Probert JC, Parker BR, Kaplan HS: Growth retardation in children after megavoltage irradiation of the spine. Cancer 1973;32:634-639.
26. Shalet SM, Beardwell CG, Morris-Jones P, Bamford FN, Ribeiro GG, Pearson D: Growth hormone deficiency in children with brain tumors. Cancer 1976;37(suppl 2):1144-1148.
27. Shalet SM, Beardwell CG, Jones PH, Pearson D: Growth hormone deficiency after treatment of acute leukaemia in children. Arch Dis Child 1976;51:489-493.
28. Shalet SM, Beardwell CG, Twomey JA, Jones PH, Pearson D: Endocrine function following the treatment of acute leukemia in childhood. J Pediatr 1977;90:920-923.
29. Shalet SM, Beardwell CG, Pearson D, Jones PH: The effect of varying doses of cerebral irradiation on growth hormone production in childhood. Clin Endocrinol (Oxf) 1976;5:287-290.
30. Shalet SM, Beardwell CG, MacFarlane IA, Jones PH, Pearson D: Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood. Acta Endocrinol (Co-penh) 1977;84:673-680.
31. Clayton PE, Shalet SM: Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991; 118:226-228.
32. Shalet SM, Whitehead E, Chapman AJ, Beardwell CG: The effects of growth hormone therapy in children with radiation-induced growth hormone deficiency. Acta Paediatr Scand 1981;70:81-86.
33. Herber SM, Dunsmore IR, Milner RD: Final stature in brain tumours other than craniopharyngioma: effect of growth hormone. Horm Res 1985;22:63-67.
34. Clayton PE, Shalet SM: The evolution of spinal growth after irradiation. Clin Oncol (R Coll Radiol) 1991;3:220-222.
35. Shalet SM, Gibson B, Swindell R, Pearson D: Effect of spinal irradiation on growth. Arch Dis Child 1987;62:461-464.
36. Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, Robison LL, et al: Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2004;89:4422-4427.
37. Lerner SE, Huang GJ, Mc Mahon D, Sklar CA, Oberfield SE: Growth hormone therapy in children after cranial/craniospinal radiation therapy: sexually dimorphic outcomes. J Clin Endocrinol Metab 2004;89:6100-6104.
38. Ogilvy-Stuart AL, Clayton PE, Shalet SM: Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994;78:1282-1286.
39. Lannering B, Albertsson-Wikland K: Improved growth response to GH treatment in irradiated children. Acta Paediatr Scand 1989;78:562-567.
40. Xu W, Janss A, Moshang T: Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metab 2003;88:4677-4681.
41. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM: Improvements in final height over 25 years in growth hormone (GH)deficient childhood survi-vors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003;88:3682-3689.
42. Farwell J, Flannery JT: Second primaries in children with central nervous system tumors. J Neurooncol 1984;2:371-375.
43. Clayton PE, Shalet SM, Gattamaneni HR, Price DA: Does growth hormone cause relapse of brain tumours? Lancet 1987;i:711-713.
44. Ogilvy-Stuart AL, Ryder WD, Gatta-maneni HR, Clayton PE, Shalet SM: Growth hormone and tumour recur-rence. BMJ 1992;304:1601-1605.
45. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, et al: Growth hormone treatment of children with brain tu-mors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85:4444-4449.
46. Moshang T Jr, Rundle AC, Graves DA, Nickas J, Johanson A, Meadows A: Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 1996;128:S4-S7.
47. Growth Hormone Research Society: Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-1870.
48. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, et al: Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87:3136-3141.
49. Murray RD, Darzy KH, Gleeson HK, Shalet SM: GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab 2002;87:129-135.
50. Mukherjee A, Tolhurst-Cleaver S, Ryder WD, Smethurst L, Shalet SM: The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy. J Clin Endocrinol Metab 2005;90:1542-1549.
51. Jostel A, Mukherjee A, Hulse PA, Shalet SM: Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 2005;62:698-705.